Skip to main
  1. Stocks
  2. 4D Molecular Therapeutics
  3. Forecast
FDMT

FDMT Stock Forecast & Price Target

FDMT Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

4D Molecular Therapeutics is compelling because 4D-150 could materially change wet AMD care by pairing single-dose, intravitreal delivery with durable aflibercept expression and RNAi-mediated VEGF suppression, potentially reducing chronic anti-VEGF injections and preserving vision more consistently than episodic standard therapy. The Phase 2b PRISM data support that thesis, showing an 78% overall treatment burden reduction over 2 years, 2.7 mean supplemental injections per patient, and 87% reduction in the recently diagnosed subgroup, while maintaining visual acuity, anatomic control, and no new safety or intraocular inflammation after the initial 28 weeks. The company’s Phase 3 4FRONT-1 and 4FRONT-2 trials, with enrollment completed ahead of projections and a Week 52 BCVA non-inferiority endpoint, appear well positioned to de-risk the program and support a credible path to broader commercial adoption.

Bears say

4D Molecular Therapeutics is facing a bearish fundamental setup because its lead 4D-150 thesis depends on late-stage retina trials that may be difficult to interpret, with baseline imbalances, noisy endpoints, and non-comparable real-world treatment patterns all creating a high risk of misleading efficacy signals. The company is also exposed to commercialization uncertainty, since even competitors like Vabysmo and Eylea HD have reduced annual injection burden by only about one injection on average, while Medicare coverage could be challenged for a therapy framed around a roughly 5 year benefit horizon in an elderly patient base. Beyond clinical risk, the gene therapy field is crowded, 4D Molecular Therapeutics’s programs are still early, and it will likely need to raise more capital to keep advancing development.

FDMT has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 4D Molecular Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

FDMT Analyst Forecast & Price Prediction

Get the latest FDMT stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in FDMT

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 4D Molecular Therapeutics (FDMT) Forecast

Analysts have given FDMT a Strong Buy based on their latest research and market trends.

According to 8 analysts, FDMT has a Strong Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

4D Molecular Therapeutics (FDMT)


FDMT Analyst Forecast & Price Prediction

Get the latest FDMT stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in FDMT

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover FDMT stock data and trends